Crescent Biopharma (CBIO) Equity Ratio (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Equity Ratio data on file, last reported at 0.92 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.92, up 118.34% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.92 (up 118.34% YoY), and the FY2025 annual result was 0.84, up 294.4% from the prior year.
• Equity Ratio grew to 0.92 in Q1 2026 per CBIO's latest filing, from 0.84 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.92 in Q1 2026 and troughed at 5.03 in Q1 2025.
• A 5-year average of 0.38 and a median of 0.85 in 2024 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 1117.1% in 2025 and fell as far as 695.51% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.83 in 2022, then increased by 2.31% to 0.85 in 2023, then sank by 151.27% to 0.43 in 2024, then jumped by 294.4% to 0.84 in 2025, then grew by 9.28% to 0.92 in 2026.
• Business Quant data shows CBIO's Equity Ratio at 0.92 in Q1 2026, 0.84 in Q4 2025, and 0.84 in Q3 2025.